Dawn Biopharmaceuticals
US company focused on gynecological cancers in women
Background to Dawn Biopharmaceuticals
Who we are
Dawn Biopharmaceuticals (DawnBio) is a preclinical stage biotech firm in the field of cancer therapy.
What we do
DawnBio's mission is now focused on providing effective, kinder therapeutic options for women suffering from OVARIAN CANCER, - and in future expects to expand its work to cover other cancer conditions related to reproductive health.
Why?
Treatments today rarely succeed in fully curing the illness - and the protocol that calls for surgery, radiation and chemo-therapy is invasive, painful, and a drawn-out process. Side-effects from certain pharmaceuticals prescribed come with extreme discomfort and added health risks.. Based on our NOVEL technology platform, our approach in Ovarian cancer care should offer much improved health outcomes, AND more gentle, patient-friendly therapeutic approaches..
Background to Ovarian Cancer - a Silent Killer
Ovarian Cancer is the deadliest reproductive cancer in women.
It develops mostly unnoticed until a late stage.
An estimated 235,000 women currently suffer from the disease in the US – with approximately 22,500 new cases diagnosed annually.
Every year approximately 14,000 patients die from the disease
Few, specific symptoms are present in the early phases of the illness, and there are no simple diagnostic tests : this leads to late discovery by doctors, at a stage where treatment options are less likely to be effective
Current therapies are almost never curative.
Multiple relapses of illness are frequent – even when early treatments have shown promise.
Metastasis occurs when the cancer spreads to other areas of the body beyond the ovaries,. worsening the prognosis for recovery
Survival rates are very poor - only 48-50% of patients are alive 5 years after ovarian cancer is first diagnosed.